The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Genetics of diabetes mellitus and diabetes complications
Cole, J. B., & Florez, J. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0278-5 · Cited by 1,797
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 976
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P. P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González‐Juanatey, J. R., Harjola, V., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 458
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
Empagliflozin in Heart Failure
Griffin, M. D., Rao, V. S., Ivey-Miranda, J. B., Fleming, J. H., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 433
Jakobsen, G. S., Småstuen, M. C., Sandbu, R., Nordstrand, N., Hofsø, D., Lindberg, M., Hertel, J. K., & Hjelmesæth, J. (2018) · JAMA · doi:10.1001/jama.2017.21055 · Cited by 358
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 247
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Levine, M. J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160613113556 · Cited by 241
7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 230
Lu, Q., Yang, L.-J., Xiao, J., Liu, Q., Ni, L., Hu, J.-W., Yu, H. J., Wu, X., & Zhang, B. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.088 · Cited by 223
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 251
Heart failure in patients with kidney disease
Tuegel, C., & Bansal, N. (2017) · Heart · doi:10.1136/heartjnl-2016-310794 · Cited by 205
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193
Aroor, A. R., Das, N. A., Carpenter, A. J., Habibi, J., Jia, G., Ramirez‐Perez, F. I., Martinez‐Lemus, L. A., Manrique‐Acevedo, C., Hayden, M. R., Duta, C., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0750-8 · Cited by 182
Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy
Byrne, N. J., Rajasekaran, N. S., Abel, E. D., & Bugger, H. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.046 · Cited by 179
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 186
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Franco, A. D., Cantini, G., Tani, A., Coppini, R., Zecchi‐Orlandini, S., Raimondi, L., Luconi, M., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.032 · Cited by 164
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021) · American Journal of Nephrology · doi:10.1159/000516213 · Cited by 143
Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment
Leancă, S. A., Crișu, D., Petriş, A. O., Afrăsânie, I., Genes, A., Costache, A. D., Tesloianu, D. N., & Costache, I. I. (2022) · Life · doi:10.3390/life12081111 · Cited by 152
Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R. A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., Angelis, A. D., Sportiello, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1008922 · Cited by 135
Lu, Y., Chang, Y., Li, T., Han, F., Li, C., Li, X., Xue, M., Cheng, Y., Meng, Z., Han, Z., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.33007 · Cited by 131
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 133
2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Budzynski, A. Z., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., Dziedzic, T., Franek, E., et al. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0001 · Cited by 128
Ganbaatar, B., Fukuda, D., Shinohara, M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173040 · Cited by 122
Liu, X., Xu, C., Xu, L., Li, X., Sun, H., Xue, M., Li, T., Yu, X., Sun, B., & Chen, L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154334 · Cited by 126
Type 2 Diabetes and Heart Failure: Challenges and Solutions
Thomas, M. C. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160606120254 · Cited by 117
Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
Wilkinson, S., Douglas, I., Stirnadel-Farrant, H. A., Fogarty, D. G., Pokrajac, A., Smeeth, L. L., & Tomlinson, L. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022768 · Cited by 116
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 122
Sukhanov, S., Higashi, Y., Yoshida, T., Mummidi, S., Aroor, A. R., Russell, J. J., Bender, S. B., DeMarco, V. G., & Chandrasekar, B. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109825 · Cited by 118
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 126
Das, N. A., Carpenter, A. J., Belenchia, A. M., Aroor, A. R., Noda, M., Siebenlist, U. K., Chandrasekar, B., & DeMarco, V. G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109506 · Cited by 109
Sodium glucose cotransporter 2 inhibition in the diabetic kidney
Novikov, A., & Vallon, V. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000187 · Cited by 106
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 101
Treatment of type 2 diabetes mellitus in the elderly
Yakaryılmaz, F. D., & Öztürk, Z. A. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.278 · Cited by 109
Cha, S., Park, Y., Yun, J., Lim, T., Song, K., Yoo, K., Ahn, Y., & Ko, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0443-4 · Cited by 105
Norris, K. C., Smoyer, K. E., Rolland, C., der Vaart, J. V., & Grubb, E. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0821-9 · Cited by 108
Unnikrishnan, A., Kalra, S., Purandare, V. B., & Vasnawala, H. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_159_17 · Cited by 100
Lovshin, J. A., Rajasekeran, H., Lytvyn, Y., Lovblom, L. E., Khan, S., Alemu, R. Z., Locke, A., LAI, V. S., He, H., Hittle, L. R., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0061 · Cited by 100
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 97
D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 91
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Mascolo, A., Napoli, R. D., Balzano, N., Cappetta, D., Urbanek, K., Angelis, A. D., Scisciola, L., Meo, I. D., Sullo, M. G., Rafaniello, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1010693 · Cited by 95
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85
Vuksan, V. V. V., Xu, Z. Z., Jovanovski, E., Jenkins, A. L., Beljan‐Zdravkovic, U., Sievenpiper, J. L., Stavro, P. M., Zurbau, A., Duvnjak, L. S., & Li, M. Z. C. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1642-0 · Cited by 87
Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults
Saeed, A., Nambi, V., Sun, W., Virani, S. S., Taffet, G. E., Deswal, A. M., Selvin, E., Matsushita, K., Wagenknecht, L. E., Hoogeveen, R. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.050 · Cited by 86
Seko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184767 · Cited by 83
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Patel, D. K., & Strong, J. L. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 83
Therapeutic medications against diabetes: What we have and what we expect
Hu, C., & Jia, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.11.008 · Cited by 81
Learning Physiology from Inherited Kidney Disorders
van der Wijst, J., Belge, H., Bindels, R. J. M., & Devuyst, O. (2019) · Physiological Reviews · doi:10.1152/physrev.00008.2018 · Cited by 77
Ishida, E., Kim-Muller, J. Y., & Accili, D. (2017) · Diabetes · doi:10.2337/db16-1213 · Cited by 76
Dougherty, J. A., Guirguis, E. H., & Thornby, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 77
Guo, Y., Ran, Z., Zhang, Y., Song, Z., Wang, L., Yao, L., Zhang, M., Xin, J., & Mao, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110684 · Cited by 73
Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002050 · Cited by 72
Self-citationQu, L., Liang, X., Tian, G., Zhang, G., Wu, Q., Huang, X., Cui, Y., Liu, Y., Shen, Z., Xiao, C., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2109 · Cited by 72
Association between prediabetes and adverse outcomes in heart failure
Mai, L., Wen, W., Qiu, M. R., Liu, X., Sun, L., Zheng, H., Cai, X., & Huang, Y. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14490 · Cited by 70
Droebner, K., Pavkovic, M., Grundmann, M., Hartmann, E., Goea, L., Nordlohne, J., Klar, J., Eitner, F., & Kolkhof, P. (2021) · American Journal of Nephrology · doi:10.1159/000518254 · Cited by 70
Cornuault, L., Rouault, P., Duplàa, C., Couffinhal, T., & Renault, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.906272 · Cited by 72
Aldafas, R., Crabtree, T. S. J., Alkharaiji, M. A., Vinogradova, Y., & IDRIS, I. R. (2023) · Age and Ageing · doi:10.1093/ageing/afad254 · Cited by 73
Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01607-4 · Cited by 69
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 67
Rhee, S. Y., Lee, J.-W., Nam, H., Kyoung, D., Shin, D. W., & Kim, D. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0206 · Cited by 64
Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
Reed, J. W. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s111991 · Cited by 67
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 72
Lingvay, I., Deanfield, J. E., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0764 · Cited by 72
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Min, J., Wu, L., Liu, Y., Song, G., Deng, Q., Wei, J. J., Yu, W., Abudureyimu, M., Pei, Z., & Ren, J. T. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121207 · Cited by 61
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
Alsereidi, F. R., Khashim, Z., Marzook, H., Al-Rawi, A. M., Salomon, T., Almansoori, M. K., Madkour, M. M., Hamam, A. M., Ramadan, M. M., Peterson, Q. P., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02481-y · Cited by 60
Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 62
Acute kidney injury in diabetic patients: A narrative review
Kaur, A., Sharma, G. S., & Kumbala, D. R. (2023) · Medicine · doi:10.1097/md.0000000000033888 · Cited by 72
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 58
Goerg, J., Sommerfeld, M., Greiner, B., Lauer, D., Seckin, Y., Kulikov, A. N., Ivkin, D. Y., Kintscher, U., Okovityi, S. V., & Kaschina, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115437 · Cited by 53
Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
Peralta, F. G., Abreu, C., Lecube, A., Bellido, D., Soto, A., Morales, C., Brito-Sanfiel, M. Á., & Umpierrez, G. E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0277-0 · Cited by 57
Sharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z. J., Hudson, L. L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 56
Hsu, J., Wang, C., Su, M.-Y. M., Lin, L., & Yang, W. (2019) · Scientific Reports · doi:10.1038/s41598-019-51949-5 · Cited by 52
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Avogaro, A., Fadini, G. P., & Prato, S. D. (2019) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 50
Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 54
CHILTON, R. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13854 · Cited by 52
Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts
Chu, Y., Zhang, C., & Xie, M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.681513 · Cited by 52
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
McGovern, A. P., Feher, M. D., Munro, N. M., & de Lusignan, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0254-7 · Cited by 48
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.019 · Cited by 49
Takebayashi, K., & Inukai, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3112w · Cited by 49
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F. N., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 52
Jain, R., Stone, J. A., Agarwal, G., Andrade, J. G., Bacon, S., BAJAJ, H. S., Baker, B., Cheng, G., Dannenbaum, D. A., Gelfer, M., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.220138 · Cited by 50
Marathias, K. P., Lambadiari, V., Markakis, K. P., Vlahakos, V., Bacharaki, D., Raptis, A. E., Dimitriadis, G., & Vlahakos, D. (2020) · American Journal of Nephrology · doi:10.1159/000507272 · Cited by 47
Srivastava, S. P., Zhou, H., Setia, O., Dardik, A., Fernandez-Hernando, C. F., & Goodwin, J. E. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019437 · Cited by 47
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 57
Coats, A. J. S., Butler, J., Tsutsui, H., Doehner, W., Filippatos, G. S., Ferreira, J. P., Böhm, M., Chopra, V., Verma, S., Nordaby, M., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13393 · Cited by 48
Loss of Mitochondrial Control Impacts Renal Health
Srivastava, S. P., Kanasaki, K., & Goodwin, J. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.543973 · Cited by 48
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105788 · Cited by 47
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
